Lataa...
Epigenetic Reprogramming and Emerging Epigenetic Therapies in CML
Chronic myeloid leukemia (CML) is a hematopoietic stem cell disorder characterized by BCR-ABL1, an oncogenic fusion gene arising from the Philadelphia chromosome. The development of tyrosine kinase inhibitors (TKIs) to overcome the constitutive tyrosine kinase activity of the BCR-ABL protein has dra...
Tallennettuna:
| Julkaisussa: | Front Cell Dev Biol |
|---|---|
| Päätekijät: | , , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
Frontiers Media S.A.
2019
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6652210/ https://ncbi.nlm.nih.gov/pubmed/31380371 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fcell.2019.00136 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|